

Nader Yatim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/155980/publications.pdf>

Version: 2024-02-01

22
papers

4,877
citations

430442

18
h-index

676716

22
g-index

23
all docs

23
docs citations

23
times ranked

12499
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 550-556.e2.	1.5	25
2	Persistent bilateral Tapia syndrome following critical COVID-19. <i>Clinical Neurophysiology</i> , 2021, 132, 505-506.	0.7	7
3	Regulation of the acetylcholine/ α 7nAChR anti-inflammatory pathway in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 11886.	1.6	35
4	Platelet activation in critically ill COVID-19 patients. <i>Annals of Intensive Care</i> , 2021, 11, 113.	2.2	61
5	Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. <i>Science Advances</i> , 2021, 7, .	4.7	27
6	Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. <i>Nature Immunology</i> , 2021, 22, 1428-1439.	7.0	110
7	Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital Mortality. <i>Arthritis and Rheumatology</i> , 2021, 73, 1976-1985.	2.9	21
8	Analysis of T-cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in patients with chilblain-like lesions during the COVID-19 pandemic. <i>British Journal of Dermatology</i> , 2021, 185, 1242-1244.	1.4	5
9	Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak*. <i>British Journal of Dermatology</i> , 2021, 185, 1176-1185.	1.4	33
10	Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. <i>Science</i> , 2020, 369, 718-724.	6.0	2,374
11	Angiotensin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. <i>Angiogenesis</i> , 2020, 23, 611-620.	3.7	204
12	RIPK3 Activation Leads to Cytokine Synthesis that Continues after Loss of Cell Membrane Integrity. <i>Cell Reports</i> , 2019, 28, 2275-2287.e5.	2.9	85
13	Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission. <i>Revue De Medecine Interne</i> , 2018, 39, 130-133.	0.6	32
14	Autophagy diminishes the early interferon- β response to influenza A virus resulting in differential expression of interferon-stimulated genes. <i>Cell Death and Disease</i> , 2018, 9, 539.	2.7	21
15	Dying cells actively regulate adaptive immune responses. <i>Nature Reviews Immunology</i> , 2017, 17, 262-275.	10.6	303
16	Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. <i>Journal of Experimental Medicine</i> , 2017, 214, 2231-2241.	4.2	100
17	Mitochondrial permeabilization engages NF- κ B-dependent anti-tumour activity under caspase-8 deficiency. <i>Nature Cell Biology</i> , 2017, 19, 1116-1129.	4.6	181
18	Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. <i>Nature Immunology</i> , 2015, 16, 850-858.	7.0	244

#	ARTICLE	IF	CITATIONS
19	RIPK1 and NF- κ B signaling in dying cells determines cross-priming of CD8 ⁺ T cells. Science, 2015, 350, 328-334.	6.0	466
20	RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis. Cell Death and Differentiation, 2014, 21, 1511-1521.	5.0	242
21	Widespread Mitochondrial Depletion via Mitophagy Does Not Compromise Necroptosis. Cell Reports, 2013, 5, 878-885.	2.9	240
22	Dying to Replicate: The Orchestration of the Viral Life Cycle, Cell Death Pathways, and Immunity. Immunity, 2011, 35, 478-490.	6.6	56